|
|
|
|
07.15-08.00 |
Meet the Expert 13: Pregnancy-related
pituitary disorders |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: TBA |
| |
|
F Kelestimur (Kayseri, Turkey) |
| |
|
|
| |
07.15-08.00 |
Meet the Expert 14: Hypoglycaemia and
insulinoma |
| |
|
LOMOND AUDITORIUM |
| |
|
Chair: TBA |
| |
|
B Eriksson (Uppsala, Sweden) |
| |
|
|
| |
07.15-08.00 |
Meet the Expert 15: Interference in hormone
assays |
| |
|
HALL 1 |
| |
|
Chair: J Barth (Leeds, UK) |
| |
|
N Goncharov (Moscow, Russia) |
| |
|
|
| |
07.15-08.00 |
Meet the Expert 16: Mouse genetics in
the identification of quantitative traits |
| |
|
FORTH ROOM |
| |
|
Chair: S Kim (London, UK) |
| |
|
G Brockman (Berlin, Germany) |
| |
|
|
| |
08.10-10.10 |
Symposium 13: Monogenic disorders illuminate
metabolic disease |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: P Froguel (Lille, France) |
S54 |
08.10 |
Genetic obesity in humans |
| |
|
S O'Rahilly (Cambridge, UK) |
S55 |
08.40 |
Specific
metabolic features in Prader- Labhart-Willi syndome (PWS) as indicators
of the underlying genetic defect |
| |
|
U Eiholzer (Zurich, Switzerland) |
S56 |
09.10 |
PPAR
gamma and human metabolic disease |
| |
|
V Chatterjee (Cambridge, UK) |
S57 |
09.40 |
Learning
from monogenic diabetes: insights into the fetal and adult b-cell |
| |
|
A Hattersley (Exeter, UK) |
| |
|
|
| |
08.10-10.10 |
Symposium 14: Steroid hormone receptors |
| |
|
HALL 1 |
| |
|
Chairs: H Klocker (Innsbruck, Austria) & F
Claessens (Leuven, Belgium) |
S58 |
08.10 |
The
ups and downs of nuclear receptor action in fat and fertility |
| |
|
M Parker (London, UK) |
S59 |
08.40 |
Chromatin
remodeling |
| |
|
F Gannon (Heidelberg, Germany) |
S60 |
09.10 |
Cell
membrane receptors of steroid hormones |
| |
|
J Brosens (London, UK) |
S61 |
09.40 |
Lysine
modifications in transcriptional regulation by steroid receptors |
| |
|
J Palvimo (Helsinki, Finland) |
| |
|
|
| |
08.10-10.10 |
Symposium 15: Anabolic hormones in sport |
| |
|
LOMOND AUDITORIUM |
| |
|
Chairs: G Tolis (Athens, Greece) & C
Strasburger (Berlin, Germany) |
S62 |
08.10 |
Overview
of anabolic steroids in sport |
| |
|
K Kuoppasalmi (Helsinki, Finland) |
S63 |
08.40 |
Detecting
growth hormone abuse in athletes |
| |
|
C Strasburger (Berlin, Germany) |
S64 |
09.10 |
Gene
doping: will the age of gene therapy usher in the age of genetic
enhancement? |
| |
|
H Sweeney (Pennsylvania, USA) |
S65 |
09.40 |
Erythropoietin |
| |
|
D Cowan (London, UK) |
| |
|
|
| |
08.10-10.10 |
Oral Communications 7: Calcium and bone |
| |
|
FORTH ROOM |
| |
|
Chair: TBA |
OC49* |
08.10 |
The
A990G polymorphism of calcium sensing receptor gene (CASR) is associated
with nephrolithiasis in patients with primary hyperparathyroidism
(PHPT) |
| |
|
C Eller-Vainicher, M Filopanti, G Vezzoli,
L Soldati, P Saeli, P Beck-Peccoz, A Spada & S Corbetta |
OC50 |
08.25 |
Congenitally
hypothyroid mice with (Pax8-/-) or without (hyt/hyt) functional
TSH receptors (TSHR) display equivalent skeletal phenotypes |
| |
|
GR Williams, R Swinhoe, E Murphy, AJ Williams,
S Costagliola, G Vassart, PGT Howell, A Boyde, F Flamant, J Samarut,
R Weiss, S Refetoff & JHD Bassett |
OC51* |
08.40 |
TSH
receptor action in osteoblasts and osteoclasts in vitro |
| |
|
E Murphy, AJ Williams, TM Galliford, S Costagliola,
G Vassart, JHD Bassett & GR Williams |
OC52 |
08.55 |
In
acromegaly, bone mineral density depends on gonadal function |
| |
|
M Kochman, W Zgliczynski, W Misiorowski,
P Zdunowski, L Papierska & S Zgliczynski |
OC53 |
09.10 |
Bone
involvement in patients with adrenal incidentalomas: role of subclinical
hypercortisolism |
| |
|
I Chiodini, F Coletti, P Epaminonda, S Di
Lembo, V Morelli, B Masserini, G Adda & M Arosio |
OC54 |
09.25 |
Adult
mice harbouring a dominant negative R384C mutation of TRa1 have
a marked increase in trabecular bone and micro-mineralisation density |
| |
|
JHD Bassett, K Nordstrom, B Vennstrom, PGT
Howell, A Boyde & GR Williams |
OC55 |
09.40 |
Thyroid
hormones stimulate osteoblast differentiation but inhibit mineralization
of bone nodules in vitro |
| |
|
AJ Williams, JC Barnard, JHD Bassett & GR
Williams |
OC56 |
09.55 |
The
Scandinavian investigation of primary hyperparathyroidism (pHPT)
- end of inclusion and preliminary results |
| |
|
JB Bollerslev, SJ Jansson, CLM Mollerup,
JN Nordenström, EL Lungren, OT Tørring, CF Franco,
JEV Varhaug, GAI Isaksen & TR Rosen |
| |
|
|
| |
10.10-10.40 |
COFFEE |
| |
|
HALL 3 |
| |
|
|
| |
10.40-11.25 |
Clinical Endocrinology Trust Lecture |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: L Rees (London, UK) |
S7 |
|
Thyroid
disease paradigms and problems |
| |
|
A Weetman (Sheffield, UK) |
| |
|
|
| |
11.35-12.20 |
Plenary 3 |
| |
|
LOMOND AUDITORIUM |
| |
|
Chair: P Bouchard (Paris, France) |
S10 |
|
Stem
cells: regeneration in type 1 diabetes |
| |
|
M Trucco (Pittsburgh, USA) |
| |
|
|
| |
11.35-12.20 |
Debate: Metformin is the treatment of
choice for polycystic ovarian syndrome |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: S Franks (London, UK) |
| |
|
For the motion: |
| |
|
R Fleming (Glasgow, UK) |
| |
|
Against the motion: |
| |
|
A Balen (Leeds, UK) |
| |
|
|
| |
12.20-13.05 |
Meet the Expert 13: Pregnancy-related
pituitary disorders |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: TBA |
| |
|
F Kelestimur (Kayseri, Turkey) |
| |
|
|
| |
12.20-13.05 |
Meet the Expert 14: Hypoglycaemia and
insulinoma |
| |
|
LOMOND AUDITORIUM |
| |
|
Chair: TBA |
| |
|
B Eriksson (Uppsala, Sweden) |
| |
|
|
| |
12.20-13.05 |
Meet the Expert 15: Interference in hormone
assays |
| |
|
HALL 1 |
| |
|
Chair: J Barth (Leeds, UK) |
| |
|
N Goncharov (Moscow, Russia) |
| |
|
|
| |
12.20-13.05 |
Meet the Expert 16: Mouse genetics in
the identification of quantitative traits |
| |
|
FORTH ROOM |
| |
|
Chair: S Kim (London, UK) |
| |
|
G Brockman (Berlin, Germany) |
| |
|
|
| |
13.05-13.35 |
LUNCH |
| |
|
HALL 3 |
| |
|
|
| |
13.35-15.35 |
Symposium 16: Disorders of melanocortin
receptor functions |
| |
|
LOMOND AUDITORIUM |
| |
|
Chair: H Biebermann (Berlin, Germany) |
S66 |
13.35 |
MC1R
variants: Mendle is quite complex enough |
| |
|
J Rees (Edinburgh, UK) |
S67 |
14.05 |
Identification
of the genes causing ACTH insensitivity |
| |
|
A Clark (London, UK) |
S68 |
14.35 |
Melanocortin
receptor mutations in humans |
| |
|
P Froguel (Lille, France) |
S69 |
15.05 |
Gs-independent
signalling of melanocortin-4 receptors |
| |
|
A Breit (Marburg, Germany) |
| |
|
|
| |
13.35-15.35 |
Symposium 17: Endocrine oncogenesis and
management of hereditary endocrine tumours |
| |
|
CLYDE AUDITORIUM |
| |
|
Chairs: B Kos Kudla (Zabrze, Poland) & E
Rossella (Pisa, Italy) |
S70 |
13.35 |
RET
function and dysfunction |
| |
|
L Fugazzola (Milan, Italy) |
S71 |
14.05 |
Novel
management strategies in medullary carcinoma of the thyroid |
| |
|
J Feldkamp (Bielefeld, Germany) |
S72 |
14.35 |
Hypoxia
inducible factor (HIF) and phaeochromocytoma |
| |
|
C Pugh (Oxford, UK) |
S73 |
15.05 |
Familial
phaeochromocytomas |
| |
|
P Plouin (Paris, France) |
| |
|
|
| |
|
|
| |
13.35-15.35 |
Clinical Management Workshop 5: Research
management workshop |
| |
|
HALL 1 |
| |
|
Chair: C Meir (Geneva, Switzerland) |
S94 |
13.35 |
Better
management of ethical review in European medicine development |
| |
|
I Klingmann (Brussels, Belgium) |
S95 |
14.15 |
Impact
of the EU Clinical Trials Directive on academic research |
| |
|
B Moulton (Dublin, Ireland) |
S96 |
14.55 |
Funding
for commercialisation of research after the biotech bubble |
| |
|
RN Seabrook (London, UK) |
| |
|
|
| |
13.35-15.35 |
Oral Communications 8: Thyroid |
| |
|
FORTH ROOM |
| |
|
Chairs: M Alevizaki (Athens, Greece) & M
Colculescu (Bucharest, Romania) |
OC57 |
13.35 |
Treatment
of experimental hyperthyroid Graves' disease with decoy TNF-family
ligand receptors suggests an essential role for BAFF in production
of thyroid stimulating antibodies |
| |
|
JA Gilbert, SL Kalled, J Moorhead, D Hess,
P Rennert, Z Li, Z Khan & J-P Banga |
OC64 |
13.50 |
Thyroid
hormone receptor TRb1 mediates Akt activation by T3 in pancreatic
b cells |
| |
|
SM Misiti, CV Verga Falzacappa, VP Patriarca,
SM Michienzi, AS Stigliano, EB Brunetti & VT Toscano |
OC59 |
14.05 |
Tri-iodothyronine
improves haemodynamic performance and is associated with improved
myocardial protection post on-pump coronary artery bypass grafting |
| |
|
AM Ranasinghe, DW Quinn, TR Graham, BE Keogh,
CJ Mascaro, SJ Rooney, IC Wilson, D Pagano, JA Franklyn & RS
Bonser |
OC60 |
14.20 |
4-Methylbenzylidene-camphor
(4MBC) causes pituitary effects comparable to hypothyroidism |
| |
|
IH Hamann, C Schmutzler, P Kirschmeyer, H
Jarry & J Köhrle |
OC61 |
14.35 |
Phosphodiesterase-resistant
PKA I agonists inhibit thyroid cancer cell growth |
| |
|
S Lucchi, D Calebiro, T de Filippis, P Porazzi,
P Beck-Peccoz & L Persani |
OC62* |
14.50 |
The
role of the thyroid hormone transporter monocarboxylate transporter
8 (MCT8) in fetal brain development |
| |
|
SR James, CJ McCabe, VE Smith, SY Chan, TG
Barrett, JA Franklyn & MD Kilby |
OC63 |
15.05 |
Gender-specific
differences in the expression of deiodinase I (Dio1) in mammals |
| |
|
C Riese, U Schweizer, J Köhrle & L
Schomburg |
OC58 |
15.20 |
Interleukin
1: the optimal cytokine target in thyroid-associated ophthalmopathy? |
| |
|
TJ Cawood, P Moriaty, C O'Farrelly & D
O'Shea |
| |
|
|
| |
15.35 |
Novartis Oncology Young Investigator
Award and BTA Award Announcements and Close of Meeting |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: S Lamberts (Rotterdam, The Netherlands) |
